Figure 3.
Figure 3. Blocking of allogeneic T-cell proliferation in response to MVA-TRICOM–infected CLL cells. (A-B) Allogeneic T cells from healthy donors were stimulated in the presence of MVA-TRICOM–infected CLL cells (patients 15 and 16, respectively) that were preincubated in the presence of 5 μg/mL monoclonal Ab directed against B7-1, ICAM-1, or LFA-3, or combination of Abs (as indicated in the figure). Error bars represent the standard error of the mean (SEM) for triplicate determinations. (C) Percentage of inhibition of proliferation of allogeneic T cells in response to MVA-TRICOM–infected CLL cells in the presence of various Abs or combination of Abs, for patients 16 (○); 12 (•); 18 (□);5(▪); 15 (▵). The line represents the average for the 5 patients analyzed. Statistical comparison between groups was based on Student 2-tailed t test.

Blocking of allogeneic T-cell proliferation in response to MVA-TRICOM–infected CLL cells. (A-B) Allogeneic T cells from healthy donors were stimulated in the presence of MVA-TRICOM–infected CLL cells (patients 15 and 16, respectively) that were preincubated in the presence of 5 μg/mL monoclonal Ab directed against B7-1, ICAM-1, or LFA-3, or combination of Abs (as indicated in the figure). Error bars represent the standard error of the mean (SEM) for triplicate determinations. (C) Percentage of inhibition of proliferation of allogeneic T cells in response to MVA-TRICOM–infected CLL cells in the presence of various Abs or combination of Abs, for patients 16 (○); 12 (•); 18 (□);5(▪); 15 (▵). The line represents the average for the 5 patients analyzed. Statistical comparison between groups was based on Student 2-tailed t test.

Close Modal

or Create an Account

Close Modal
Close Modal